Literature DB >> 32783166

JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).

Kazuya Shimoda1, Naoto Takahashi2, Keita Kirito3, Noriyoshi Iriyama4, Tatsuya Kawaguchi5, Masahiro Kizaki6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32783166     DOI： 10.1007/s12185-020-02964-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

Review 1.  Treatment options and pregnancy management for patients with PV and ET.

Authors:  Yoko Edahiro
Journal:  Int J Hematol       Date:  2022-04-08       Impact factor: 2.490

2.  Analysis of the Clinical Significance and Safety of Interferon in the Treatment of Chronic Myeloproliferative Tumors.

Authors:  Fenglei Yin; Juan Yin; Weixing Xu; Shuchen Li; Wei Zhang; Juan Wang
Journal:  J Oncol       Date:  2022-05-16       Impact factor: 4.501

3.  Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study.

Authors:  Yoshinori Hashimoto; Tomoki Ito; Akihiko Gotoh; Mika Nakamae; Fumihiko Kimura; Michiaki Koike; Keita Kirito; Hideho Wada; Kensuke Usuki; Takayuki Tanaka; Takehiko Mori; Satoshi Wakita; Toshiki I Saito; Akiko Kada; Akiko M Saito; Kazuya Shimoda; Yuka Sugimoto; Toshiro Kurokawa; Akihiro Tomita; Yoko Edahiro; Koichi Akashi; Itaru Matsumura; Katsuto Takenaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2021-11-02       Impact factor: 2.490

Review 4.  JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.

Authors:  Bilal Rah; Rafiq A Rather; Gh Rasool Bhat; Abdul Basit Baba; Ifra Mushtaq; Muzamil Farooq; Tahira Yousuf; Sadaf B Dar; Sabra Parveen; Rukhsana Hassan; Fozia Mohammad; Iqbal Qassim; Abida Bhat; Shazia Ali; Mahrukh Hamid Zargar; Dil Afroze
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

5.  Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose.

Authors:  Norio Komatsu; Yoshinori Hashimoto; Terumi Baba; Manami Otsuka; Takafumi Akimoto; Jovelle Fernandez
Journal:  Int J Hematol       Date:  2022-05-27       Impact factor: 2.319
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.